ArticleGastroenterology2023
Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.
Article in Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Implications and risk of new versus persisting intraductal papillary mucinous neoplasms after pancreatic surgery: meta-analysis.BJS open · 2026Pooled it
- Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Small cyst size and lack of growth as negative predictors of malignant transformation in low-risk intraductal papillary mucinous neoplasms of the pancreas: A systematic review and meta-analysis.United European gastroenterology journal · 2025Pooled it
- Global Prevalence of Pancreatic Cystic Lesions in the General Population on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Pooled it
- MRCP surveillance of low-risk branch-duct IPMNs: longitudinal size changes and clinical outcomes in a real-world cohort.Abdominal radiology (New York) · 2026Article
- Discontinuing Surveillance of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms in Routine Practice: An External Application of the "Trivial" Criteria and the Resources it Would Release in Fourteen Health Systems.United European gastroenterology journal · 2026Article
- Cancer Risk After Initial Surveillance of Intraductal Papillary Mucinous Neoplasms (IPMNs): Are We Missing the Window for Prevention?Annals of surgical oncology · 2026Article
- Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-derived cancer and concomitant pancreatic ductal adenocarcinoma.Japanese journal of radiology · 2026Review
- Procedure-specific morbidity and pathologic assessment after resection of small (≤20 mm) pancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2026Observational
- Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: History, Myths, and Realities Between Past and Future.Medical sciences (Basel, Switzerland) · 2026Review
- The Surveillance Strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for Discontinuation.Annals of surgery · 2026Article
- A bibliometric analysis of research trends and future directions in early detection of pancreatic cancer.Discover oncology · 2026Article
- Real world evaluation of multiparametric MRI using diffusion weighted imaging and MRCP for pancreatic cancer surveillance.Scientific reports · 2026Observational
- Prevalence and Size-Based Risk Categorization of Pancreatic Cysts Among Asymptomatic Individuals With Screening MRI.JAMA network open · 2026Article
- Use of an Algo-Based Decision-Making Tool to Compare Real-Life Clinical Practice in a Single Tertiary Center with the Kyoto IPMN Surveillance Recommendations.Journal of clinical medicine · 2026Article
- Case Report: Metachronous oncocytic and colloid carcinoma arising from pancreatic intraductal neoplasms over four decades.Frontiers in oncology · 2026Article
- Liquid biopsies for risk stratification of intraductal papillary mucinous neoplasms.Surgery open science · 2025Article
- Pancreatic Cystic Lesions in the Older Patient: A Review of Clinical Guidelines and Management.Current gastroenterology reports · 2025Review
- The Differential Diagnosis and Management of Pancreatic Cystic Neoplasms.Deutsches Arzteblatt international · 2025Review
- Small and Stable Pancreatic Cysts Are Reassuring During Surveillance: Results From the PACYFIC Trial.United European gastroenterology journal · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
38 authors at 17 institutions in 9 countries.
Funding
Abstract
BACKGROUND &
aimsCurrently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with questionable benefits regarding cancer prevention. This study sought to identify patients in whom the risk of cancer is equivalent to an age-matched population, thereby justifying discontinuation of surveillance.
methodsInternational multicenter study involving presumed BD-IPMN without worrisome features (WFs) or high-risk stigmata (HRS) at diagnosis who underwent surveillance. Clusters of individuals at risk for cancer development were defined according to cyst size and stability for at least 5 years, and age-matched controls were used for comparison using standardized incidence ratios (SIRs) for pancreatic cancer.
resultsOf 3844 patients with presumed BD-IPMN, 775 (20.2%) developed WFs and 68 (1.8%) HRS after a median surveillance of 53 (interquartile range 53) months. Some 164 patients (4.3%) underwent surgery. Of the overall cohort, 1617 patients (42%) remained stable without developing WFs or HRS for at least 5 years. In patients 75 years or older, the SIR was 1.12 (95% CI, 0.23-3.39), and in patients 65 years or older with stable lesions smaller than 15 mm in diameter after 5 years, the SIR was 0.95 (95% CI, 0.11-3.42). The all-cause mortality for patients who did not develop WFs or HRS for at least 5 years was 4.9% (n = 79), and the disease-specific mortality was 0.3% (n = 5).
conclusionsThe risk of developing pancreatic malignancy in presumed BD-IPMN without WFs or HRS after 5 years of surveillance is comparable to that of the general population depending on cyst size and patient age. Surveillance discontinuation could be justified after 5 years of stability in patients older than 75 years with cysts <30 mm, and in patients 65 years or older who have cysts ≤15 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.